Search

Your search keyword '"Villa, Erica"' showing total 815 results

Search Constraints

Start Over You searched for: Author "Villa, Erica" Remove constraint Author: "Villa, Erica"
815 results on '"Villa, Erica"'

Search Results

1. Scanning the aged to minimize missed injury: An EAST multicenter study

2. Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)

4. Expert opinion on bleeding risk from invasive procedures in cirrhosis

5. Expert opinion on bleeding risk from invasive procedures in cirrhosis

6. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity.

8. Use of albumin infusion for cirrhosis-related complications: An international position statement

9. Long-Term SARS-CoV-2 Antibody Seroprevalence in Blood Donors, Italy

11. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

12. THU-446 VETC predicts benefit of anti-angiogenic drugs in advanced HCC

13. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

14. Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study

15. Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study

16. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

17. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

19. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis.

20. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury.

21. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

22. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

23. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

24. Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19

25. Deregulated neddylation in liver fibrosis

26. A morphological method for ammonia detection in liver.

28. Differential Impact of Tumor Endothelial Angiopoietin-2 and Podoplanin in Lymphatic Endothelial Cells on HCC Outcomes with Tyrosine Kinase Inhibitor Treatment According to Sex.

29. Hepatitis E Virus: What More Do We Need to Know?

31. Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study

32. Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)

33. Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin‐1

34. Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer

36. Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study

37. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

38. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis

39. GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study

40. Parental leave, childcare policies, and workplace bias for hepatology professionals: A national survey

42. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis

44. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

46. A machine learning enabled score based on large varices predicts 5- and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with compensated advanced chronic liver disease

48. TIPS under-dilation strategy with new controlled expansion endoprosthesis: a hemodynamic and imaging confirmation of its feasibility

49. GALAD score outperforms aMAP and ALBI scores in the 5- and 10-year prediction of hepatocellular carcinoma (HCC) development in patients with compensated advanced chronic liver disease (cACLD): a 12-year prospective study

50. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study

Catalog

Books, media, physical & digital resources